• 1
    Østergaard H, Bjelke JR, Hansen L, Petersen LC, Pedersen AA, Elm T, Møller F, Hermit MB, Holm PK, Krogh TN, Petersen JM, Ezban M, Sørensen BB, Andersen MD, Agersø H, Ahmadian H, Balling KW, Christiansen ML, Knobe K, Nichols TC et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 2011; 118: 233341.
  • 2
    Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 2009; 102: 63444.
  • 3
    Peters RT, Low SC, Kamphaus GD, Dumont JA, Amari JV, Lu Q, Zarbis-Papastoitsis G, Reidy TJ, Merricks EP, Nichols TC, Bitonti AJ. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010; 115: 205764.
  • 4
    Begbie ME, Mamdani A, Gataiance S, Eltringham-Smith LJ, Bhakta V, Hortelano G, Sheffield WP. An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice. Thromb Haemost 2005; 94: 113847.
  • 5
    Chang RY, Brock J, Griffith MJ, Monroe DM. Glycosylation of the activation peptide of FIX determines plasma half-life. J Thromb Haemost 2007; 5 (Suppl. 2): O-M-088.
  • 6
    Griffith MJ, Monroe DM, van Cott KE, Walker A, Waugh S, Kumar A, Drohan WN. N-glycan sialylation is important for in vivo recovery of recombinant factor IX. J Thromb Haemost 2007; 5 (Suppl. 2): P-M-043.
  • 7
    Flintegaard TV, Thygesen P, Rahbek-Nielsen H, Levery SB, Kristensen C, Clausen H, Bolt G. N-glycosylation increases the circulatory half-life of human growth hormone. Endocrinology 2010; 151: 532636. and references therein.
  • 8
    Bolt G, Steenstrup TD, Kristensen C. All post-translational modifications except propeptide cleavage are required for optimal secretion of coagulation factor VII. Thromb Haemost 2007; 98: 98897.
  • 9
    Gillis S, Furie BC, Furie B, Patel H, Huberty MC, Switzer M, Foster WB, Scoble HA, Bond MD. γ-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function. Protein Sci 1997; 6: 18596.
  • 10
    Gui T, Lin H-F, Jin D-Y, Hoffman M, Straight DL, Roberts HR, Stafford DW. Circulating and binding characteristics of wild-type factor IX and Gla domain mutants in vivo. Blood 2002; 100: 1538.
  • 11
    Gailanu D. Factor IX binding to collagen. J Thromb Haemost 2009; 7: 18402.